Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- John Metcalfe, MD, PhD, MPH
University of California, San Francisco
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Les Centres Gheskio Clinical Research Site (gheskio-Inlr) Crs
Port-au-Prince, Haiti
- Byramjee Jeejeebhoy Medical College (bjmc) Crs
Pune, India
- Malawi Crs
Lilongwe, Central Region, Malawi
- Blantyre Crs
Blantyre, Malawi
- Caprisa Ethekwini Crs
Durban, KwaZulu-Natal, South Africa
- Milton Park Crs
Harare, Zimbabwe
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 5 Nov 2021
- Primary completion
- 24 Jun 2024
- Completion
- 24 Jun 2025
- Last update posted
- 8 Jul 2026
- Registered enrollment
- 104
- Registry id
- NCT04311502
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.